1-(2-aminooxy-ethyl)-pyrrolidin-2-one | 511531-60-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(2-aminooxy-ethyl)-pyrrolidin-2-one
• 英文别名: 1-[2-(Aminooxy)ethyl]pyrrolidin-2-one；1-(2-aminooxyethyl)pyrrolidin-2-one
• CAS: 511531-60-5
• 化学式: C₆H₁₂N₂O₂
• mdl: MFCD11521347
• 分子量: 144.173
• InChiKey: GRLWXERNPGKSAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090

反应信息

• 作为产物：
  描述：

  N-羟乙基-2-吡咯烷酮 在 偶氮二甲酸二异丙酯 、 三苯基膦 、 甲基肼 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 1-(2-aminooxy-ethyl)-pyrrolidin-2-one
  参考文献：
  名称：

  EP1674452

  摘要：

  公开号：

文献信息

• 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors
  申请人：Isshiki Yoshiaki

  公开号：US20070105859A1

  公开（公告）日：2007-05-10

  A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below: wherein, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Q, R 8 , and R 9 have the same meanings as R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Q, R 8 , and R 9 in the specification.

  本发明的化合物或其药学上可接受的盐由下式（1）表示：其中，R1、R2、R3、R4、R5、R6、Q、R8和R9在说明书中具有与R1、R2、R3、R4、R5、R6、Q、R8和R9相同的含义。
• 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US08084645B2

  公开（公告）日：2011-12-27

  A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below: wherein, R1, R2, R3, R4, R5, R6, Q, R8, and R9 have the same meanings as R1, R2, R3, R4, R5, R6, Q, R8, and R9 in the specification.

  本发明的化合物或其药学上可接受的盐，由下式（1）表示：其中，R1、R2、R3、R4、R5、R6、Q、R8和R9在说明书中具有与R1、R2、R3、R4、R5、R6、Q、R8和R9相同的含义。
• NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
  申请人：MEIJI SEIKA PHARMA CO., LTD.

  公开号：US20150141401A1

  公开（公告）日：2015-05-21

  A diazabicyclooctane compound, which is a beta-lactame inhibitor, represented by the following formula (I): wherein A represents Ra(Rb)N— or RcO—; B represents NH or NC 1-6 alkyl; C represents benzyl, H or SO 3 M, wherein M represents H, an inorganic or an organic cation; Ra and Rb represent H, C 1-6 alkyl or acyl; Rc represents C 1-6 alkyl or a heterocyclyl; A is unsubstituted or substituted with 0 to 4 substituents Fn1, wherein Fn1 represents C 1-6 alkyl, O═, or Rg-(CH 2 ) 0-3 —, wherein Rg represents a heterocyclyl, phenyl, heteroaryl, acyl, RdO 2 S—, Re(Rf)N—, Re(Rf)NCO—, ReO—, ReOCO— or a protective group, wherein Rd represents C 1-6 alkyl or MO—; Re and Rf represent H or C 1-6 alkyl, and a heterocycle having at least one nitrogen atom may be formed between Ra and Rb, between Rc and B, or between Re and Rf.

  这是一种二氮杂双环辛烷化合物，是一种β-内酰胺酶抑制剂，化学式为(I)，其中A代表Ra(Rb)N—或RcO—；B代表NH或NC1-6烷基；C代表苄基、氢或SO3M，其中M代表氢、无机或有机阳离子；Ra和Rb代表氢、C1-6烷基或酰基；Rc代表C1-6烷基或杂环基；A未被取代或被0至4个取代基Fn1取代，其中Fn1代表C1-6烷基、O═或Rg-(CH2)0-3—，其中Rg代表杂环基、苯基、杂环芳基、酰基、RdO2S—、Re(Rf)N—、Re(Rf)NCO—、ReO—、ReOCO—或保护基，其中Rd代表C1-6烷基或MO—；Re和Rf代表氢或C1-6烷基，Ra和Rb之间、Rc和B之间或Re和Rf之间可以形成至少一个含有氮原子的杂环。
• BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
  申请人：MEIJI SEIKA PHARMA CO., LTD.

  公开号：US20160024090A1

  公开（公告）日：2016-01-28

  A diazabicyclooctane compound, which is a beta-lactame inhibitor, represented by the following formula (I): wherein A represents Ra(Rb)N— or RcO—; B represents NH or NC 1-6 alkyl; C represents benzyl, H or SO 3 M, wherein M represents H, an inorganic or an organic cation; Ra and Rb represent H, C 1-6 alkyl or acyl; Rc represents C 1-6 alkyl or a heterocyclyl; A is unsubstituted or substituted with 0 to 4 substituents Fn1, wherein Fn1 represents C 1-6 alkyl, O═, or Rg-(CH 2 ) 0-3 —, wherein Rg represents a heterocyclyl, phenyl, heteroaryl, acyl, RdO 2 S—, Re(Rf)N—, Re(Rf)NCO—, ReO—, ReOCO— or a protective group, wherein Rd represents C 1-6 alkyl or MO—; Re and Rf represent H or C 1-6 alkyl, and a heterocycle having at least one nitrogen atom may be formed between Ra and Rb, between Rc and B, or between Re and Rf.

  一种二氮杂双环辛烷化合物，其为β-内酰胺酶抑制剂，由以下式子（I）表示：其中，A代表Ra（Rb）N-或RcO-；B代表NH或NC1-6烷基；C代表苄基、H或SO3M，其中M代表H、无机或有机阳离子；Ra和Rb代表H、C1-6烷基或酰基；Rc代表C1-6烷基或杂环基；A未被取代或被0至4个Fn1取代，其中Fn1代表C1-6烷基、O═或Rg-(CH2)0-3-，其中Rg代表杂环基、苯基、杂环芳基、酰基、RdO2S-、Re(Rf)N-、Re(Rf)NCO-、ReO-、ReOCO-或保护基，其中Rd代表C1-6烷基或MO-；Re和Rf代表H或C1-6烷基，Ra和Rb之间、Rc和B之间或Re和Rf之间可以形成至少一个含有氮原子的杂环。
• NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND USE THEREOF AS MEK INHIBITOR
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1674452A1

  公开（公告）日：2006-06-28

  A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below: wherein, R1, R2, R3, R4, R5, R6, Q, R8, and R9 have the same meanings as R1, R2, R3, R4, R5, R6, Q, R8, and R9 in the specification.

  本发明的化合物或其药学上可接受的盐如下式（1）所示： 其中，R1、R2、R3、R4、R5、R6、Q、R8 和 R9 与说明书中的 R1、R2、R3、R4、R5、R6、Q、R8 和 R9 具有相同的含义。